![]() | Gullo, C.* , Laverdeur, E.* , Dancre, M., Peiffer, R., Boumahd, Y., Agirman, F., Maloujahmoum, N., Désiront, L., Thiry, M., Rademaker, G., Bellahcene, A., & Peulen, O. (28 November 2025). Focal adhesion assembly and cell migration require myoferlin in PDAC cell lines. Scientific Reports, 15 (1). doi:10.1038/s41598-025-27134-2 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
![]() | Peiffer, R., Laverdeur, E., Gaigneaux, A., Boumahd, Y., Gullo, C., Rademaker, G., Crake, R., Lavergne, A., Maloujahmoum, N., Agirman, F., Herfs, M., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (2025). Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts. EMBO Journal. doi:10.1038/s44318-025-00570-6 Peer Reviewed verified by ORBi |
![]() | Boumahd, Y., Colin, G., Peiffer, R., Gullo, C., Agirman, F., Maloujahmoum, N., Coucke, P., Bellahcene, A., & Peulen, O. (04 July 2024). Modulation of radiosensitivity by myoferlin pharmacological targeting in human pancreatic cancer cell lines [Poster presentation]. IsCam 2024, Bruxelles, Belgium. |
![]() | Boumahd, Y., Colin, G., Peiffer, R., Gullo, C., Agirman, F., Maloujahmoum, N., Coucke, P., Bellahcene, A., & Peulen, O. (04 September 2023). Modulation of radiosensitivity by myoferlin pharmacological targeting in human pancreatic cancer cell lines [Poster presentation]. GIGA day 2023, Liège, Belgium. |
![]() | Peiffer, R., Boumahd, Y., Gullo, C., Agirman, F., Maloujahmoum, N., Masamune, A., Letellier Elisabeth, Bellahcene, A., & Peulen, O. (03 May 2023). Myoferlin, a new drug target in pancreatic CAFs, promotes desmoplasia and tumor aggressiveness [Poster presentation]. Gordon Research Conference - Pancreatic Diseases, Lucca, Italy. |
![]() | Peiffer, R., Boumahd, Y., Gullo, C., Crake, R., Letellier, E., Bellahcene, A., & Peulen, O. (22 December 2022). Cancer-Associated Fibroblast Diversity Shapes Tumor Metabolism in Pancreatic Cancer. Cancers, 15 (1), 61. doi:10.3390/cancers15010061 Peer Reviewed verified by ORBi |
![]() | Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (30 September 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Investigation of STAT3 involvement [Poster presentation]. BACR 2022, Gand, Belgium. |
![]() | Peiffer, R., Boumahd, Y., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Masamune Atsushi, Letellier Elisabeth, Bellahcene, A., & Peulen, O. (30 September 2022). The role of myoferlin in PDAC fibroblasts and desmoplasia [Poster presentation]. BACR - annual meeting 2022, Ghent, Belgium. |
![]() | Peiffer, R., Boumahd, Y., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Asamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (06 September 2022). The role of myoferlin in pancreatic cancer fibroblasts and desmoplasia [Poster presentation]. GIGA Day 2022, Liège, Belgium. |
![]() | Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Gullo, C., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Investigation on the involvement of STAT3 [Paper presentation]. GIGA Day 2022, Liège, Belgium. |
Gullo, C., Boumahd, Y., Peiffer, R., Anania, S., Agirman, F., Maloujahmoum, N., Thiry, M., Bellahcene, A., & Peulen, O. (2022). Myoferlin controls beta actin cytoskeleton integrity in pancreas cancer [Paper presentation]. GIGA Day 2022, Liège, Belgium. |